ClinicalTrials.gg
RecruitingNCT05784259Updated Dec 15, 2023

Development of Transdiagnostic Single-session Treatment

An interventional study of Transdiagnostic single-session treatment in Anxiety Disorders, Depression and Stress Disorder, sponsored by Luleå Tekniska Universitet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Luleå Tekniska Universitet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Anxiety Disorders with a site in Sweden — 25 open to participants now, 38 under way, none of them phase 3. Anxiety Disorders · Sweden.

Planned enrollment
22nd of 132
300 · median 97
Started
2023
with 10 others
No phase
113 of 151
22 open now
Primary completion
2024-12
later than 7 of 37 live
Registered
107th of 151
by date

Among the 151 studies in Anxiety Disorders with a site in Sweden, this one is the 22nd largest by planned enrollment of the 132 interventional ones that give a count, is one of 11 that started in 2023, is one of 113 with no phase, reaches primary completion later than 7 of the 37 other live ones, and was the 107th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

25 of the 151 studies in Anxiety Disorders with a site in Sweden are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Anxiety Disorders with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is:

  • Will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress?
  • Will the transdiagnostic treatment program decrease transdiagnostic risk factors?
  • Will the transdiagnostic treatment program decrease the measured risk factors equally?
  • Will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally?
  • Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors?
  • Will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms?
  • Have the participants been able to generalize the skills taught in the program(qualitative)?
  • Within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?
Read the detailed description

The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress.

The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions.

The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.

03

Conditions studied

  • Anxiety Disorders
  • Depression
  • Stress Disorder

Keywords

  • transdiagnostic
  • single-session
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the criteria for anxiety, mood disorder, or stress diagnosis
  • Symptoms are mild to moderate in severity

Exclusion criteria

Exclusion Criteria:

  • Already in ongoing psychotherapy
  • Within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose
  • Has a comorbid personality disorder
  • Has a risk of suicide deemed other than low
  • Has other severe psychological disorders outside the scope of primary care
  • Is in a severely stressful social situation deemed incompatible with psychotherapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Control group
  • Experimental
    Treatment group

    Transdiagnostic single-session treatment

    Behavioral: Transdiagnostic single-session treatment

Interventions

  • BehavioralTransdiagnostic single-session treatment

    Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation

06

What researchers measure

Primary outcomes

  1. Anxiety, Depression and Stress symptoms post-treatment

    Measured using DASS-21

    Time frame: 3 weeks post-treatment

  2. Anxiety, Depression and Stress symptoms follow-up

    Measured using DASS-21

    Time frame: 6 months post-treatment

  3. Anxiety sensitivity post-treatment

    Measured using BSQ, fear of bodily sensations related to anxiety

    Time frame: 3 weeks post-treatment

  4. Anxiety sensitivity follow-up

    Measured using BSQ, fear of bodily sensations related to anxiety

    Time frame: 6 months post-treatment

  5. Experiential avoidance post-treatment

    Measured using AFQ-Y8, psychological flexibility

    Time frame: 3 weeks post-treatment

  6. Experiential avoidance follow-up

    Measured using AFQ-Y8, psychological flexibility

    Time frame: 6 months post-treatment

  7. Mindfulness post-treatment

    Measured using FFMQ, mindfulness

    Time frame: 3 weeks post-treatment

  8. Mindfulness follow-up

    Measured using FFMQ, mindfulness

    Time frame: 6 months post-treatment

  9. Alexithymia post-treatment

    Measured using TAS-20, mindfulness

    Time frame: 3 weeks post-treatment

  10. Alexithymia follow-up

    Measured using TAS-20, mindfulness

    Time frame: 6 months post-treatment

  11. Generalization

    Qualitative interview with a few selected patients to review their experience of the treatment, its effectiveness and their ability to use the techniques taught.

    Time frame: 6 months post-treatment

Secondary outcomes

  1. Additional treatment

    It will be recorded if patients sought additional care after single-session treatment as well as type of care.

    Time frame: 6 months post-treatment

07

Study locations

1 of 1 sites recruiting
  • Region Norrbotten, Primary care
    Luleå, Norrbotten, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 14 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Jan 2025
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05784259
Lead sponsor
Luleå Tekniska Universitet
Collaborators
Region Norrbotten
Responsible party
John Näsling (Lic. psychologist / Doctoral student, Luleå Tekniska Universitet) — Principal investigator
First posted
Mar 24, 2023
Start date
Oct 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Dec 15, 2023

Study contacts

John Näsling, Master
Contact
john.nasling@ltu.se
+4673 080 77 67
John Näsling, Master
principal investigator · Luleå tekniska universitet/Region Norrbotten

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion